[Clinical efficiency and safety of riamilovir under various dosage regimens for treatment of acute respiratory viral infections in adults].

K V Zhdanov O V Maltsev K V Kasyanenko K V Kozlov V S Sukachev N I Lvov V V Sharabkhanov A A Litvinov

Published in: Terapevticheskii arkhiv (2023)

Riamilovir has shown clinical efficacy and a good safety profile in in both treatment regimens. The dosage regimen of 1250 mg per day led to more significant clinical effects and to 100% elimination of ARVI pathogens in the study group by the 6th day of hospitalization.

Keyphrases

liver failure
intensive care unit
hepatitis b virus
aortic dissection